Showing results (321-330 of 933) with videos related to

Sort By:
Pageof 94
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2008
Phase I trial of nelarabine in indolent leukemiasVarsha Gandhi, Constantine Tam, Susan O'Brien, et al.
Cancer|July 13, 2002
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapyEhab Atallah, Moshe Talpaz, Susan O'brien, et al.
Cancer|August 31, 2010
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapyFarshid Dayyani, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|May 26, 2010
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapyDushyant Verma, Hagop Kantarjian, Jianqin Shan, et al.
Cancer Chemotherapy and Pharmacology|August 31, 2002
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignanciesApostolia-Maria Tsimberidou, Deborah Thomas, Susan O'Brien, et al.
British Journal of Haematology|August 16, 2005
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell deathGeorgios V Georgakis, Yang Li, Robin Humphreys, et al.
Cancer|February 22, 2002
Central nervous system relapse in adults with acute lymphoblastic leukemiaUsha R Surapaneni, Jorge E Cortes, Deborah Thomas, et al.
Leukemia & Lymphoma|July 15, 2006
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center SeriesApostolia-Maria Tsimberidou, Maribel Tirado-Gomez, Michael Andreeff, et al.
Blood|April 17, 2009
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapyAlfonso Quintás-Cardama, Hagop Kantarjian, Dan Jones, et al.
British Journal of Haematology|June 6, 2003
T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibitionNam H Dang, Ugur Aytac, Kazuya Sato, et al.
Pageof 94